Clinical Trial Search

Primary: Percentage of Participants With Mucosal Healing and No Deep Ulcerations — 30.3; 45.9 percentage of participants — p=0.010

Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants

Primary: Percentage of Participants Who Achieved Clinical Remission at Week 4 — 43.7; 43.5 percentage of participants — p=0.939

Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526

Primary: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 — 144; 36 Participants — p=<0.0001

Primary: Percentage of Participants Achieving Endoscopic Remission at Week 26 — 34.5 percentage of participants

Primary: Number of Participants With Moderate to Severe UC Who Showed Clinical Remission as Defined by the MMS — 9; 17; 22 Participants

Primary: Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation — 12.1; 15.2 percentage of participants…

Primary: Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16 — 0; 10.3; 8.1; 8.3 percentage of participants — p=0.056

Primary: Induction Phase: Cohort 1: Percentage of Participants With Clinical Remission at Week 14 — 11.9; 20.00; 27.3 Percentage of Particiapnts

Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393

Primary: Number of Participants With Clinical Response 70 at Week 4 — 14; 13; 18; 16 participants

Primary: Number of Participants With Clinical Response at Week 6 — 31; 48; 45; 52 Participants — p=0.005

Primary: Part I: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 8 — -60.0; -103.6 units on a scale

Primary: Mean Extent of Exposure - Duration in Days — 159.2 days

Primary: Percentage of Participants With Remission at Week 8 — 13.3; 23.1; 14.3; 19.5 percentage of participants — p=0.76

Primary: Percentage of Participants in Clinical Remission (as Defined by a Crohn's Disease Activity Index [CDAI] Score of Less Than [<] 150 Points) at Week 8 — 36.67; 43.53…

Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale

Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8 — 26.7; 49.2 Percentage of Participants — p==0.01

Primary: Percentage of Participants With Remission at Week 8 — 16.6; 3.6 percentage of participants — p=0.0005

Primary: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 — 29.1; 49.5 percentage of participants — p=<0.0001

Primary: Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12…

Primary: The Crohn's Disease Activity Index (CDAI)-70 Response Rate at Week 8 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg — 30.6; 35.0; 49.3…

Primary: Number of Subjects Without Mucosal Ulceration at Week 12 — 8; 17 Subjects — p=0.056

Primary: Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or…

Primary: Number of Participants With Clinical Remission at Week 44 — 47; 63; 68 participants — p=0.040

Primary: Percentage of Participants in Clinical Remission at Week 12 — 2.7; 11.3; 16.7; 15.5 percentage of participants — p=0.0213

Primary: CDAI Clinical Response -100 at Week 8 — 19; 11 Participants

Primary: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 — 21.1; 38.9 percentage of participants — p=<0.0001

Primary: Number of Participants Stratified by Treatment Patterns Associated With Biologics Agents Use or Non-biological Therapy in Participants With Moderate to Severe UC and CD…